REGNMEDIUM SIGNALFINANCIAL10-K

Regeneron showed solid revenue growth of 21% but experienced declining operating income as R&D expenses expanded notably.

The company appears to be in an investment phase, prioritizing R&D spending growth over near-term profitability optimization. The trademark additions for "Lynozyfic" and updates to manufacturing language around EYLEA HD suggest active pipeline progression, though the FDA inspection delay at the Catalent facility indicates some regulatory hurdles remain.

Comparing 2026-02-04 vs 2025-02-05View on EDGAR →
FINANCIAL ANALYSIS

Regeneron demonstrated strong top-line momentum with revenue growing over 20% while maintaining robust cash generation, as evidenced by operating cash flow reaching $5.0B and increased share buybacks of $3.4B. However, profitability came under pressure with operating income declining 10% as R&D expenses grew 14% to $5.9B, reflecting the company's continued investment in its development pipeline. The balance sheet remains solid with cash positions strengthening to $3.1B, though total liabilities increased modestly alongside business expansion.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
+32.1%
$2.6B→$3.4B

Share repurchases increased 32.1% — management returning capital, signals confidence in intrinsic value.

Cash & Equivalents
Balance Sheet
+25.3%
$2.5B→$3.1B

Cash grew 25.3% — improving liquidity position supports investment and shareholder returns.

Interest Expense
P&L
+22.9%
$59.4M→$73.0M

Interest costs rose 22.9% — monitor debt levels and coverage ratio in rising rate environment.

Revenue
P&L
+20.8%
$4.9B→$5.9B

Revenue growing 20.8% — solid top-line momentum, watch margins for quality of growth.

R&D Expense
P&L
+14%
$5.1B→$5.9B

R&D investment increased 14% — signals commitment to future product development, though near-term margin impact.

Operating Cash Flow
Cash Flow
+12.6%
$4.4B→$5.0B

Operating cash flow grew 12.6% — strong conversion of earnings to cash, healthy business fundamentals.

Current Liabilities
Balance Sheet
+10.8%
$3.9B→$4.4B

Current liabilities rose 10.8% — increased short-term obligations, watch current ratio.

Total Liabilities
Balance Sheet
+10.7%
$8.4B→$9.3B

Liabilities increased 10.7% — monitor debt-to-equity ratio and interest coverage.

Operating Income
P&L
-10.3%
$4.0B→$3.6B

Operating profitability softening — costs rising faster than revenue, watch for margin recovery plan.

LANGUAGE CHANGES
NEW — 2026-02-04
PRIOR — 2025-02-05
ADDED
Management's Discussion and Analysis of Financial Condition and Results of Operations 74 Item 7A.
Form 10-K Summary 94 SIGNATURE PAGE 95 "Altibodies ," "ARCALYST ," "Evkeeza ," "EYLEA ," "EYLEA HD ," "Inmazeb ," "Libtayo ," "Lynozyfic ," "Ordspono ," "Praluent " (in the United States), "REGEN-COV ," "Regeneron ," "Regeneron Genetics Center ," "RGC ," "STEM-Fueled ," " Veloci-Bi ," " VelociGene ," " VelociHum ," " VelociMab ," " VelocImmune ," " VelociMouse ," " VelociSuite ," " VelociT ," "Veopoz ," and "ZALTRAP " are trademarks of Regeneron Pharmaceuticals, Inc.
In evaluating such statements, shareholders and potential investors should specifically consider the various factors identified under Part I, Item 1A.
(c) We record global net product sales of Libtayo and pay Sanofi a royalty on such sales (d) We record net product sales of Praluent in the United States.
Approved EC for extended dosing intervals up to 6 months (24 weeks) in wAMD and DME U.S.
+7 more — sign up free →
REMOVED
Management's Discussion and Analysis of Financial Condition and Results of Operations 70 Item 7A.
Form 10-K Summary 91 SIGNATURE PAGE 92 "Altibodies ," "ARCALYST ," "Evkeeza ," "EYLEA ," "EYLEA HD ," "Inmazeb ," "Libtayo ," "Ordspono ," "Praluent " (in the United States), "REGEN-COV ," "Regeneron ," "Regeneron Genetics Center ," "RGC ," "Veloci-Bi ," "VelociGene ," "VelociHum ," "VelociMab ," "VelocImmune ," "VelociMouse ," "VelociSuite ," "VelociT ," "Veopoz ," and "ZALTRAP " are trademarks of Regeneron Pharmaceuticals, Inc.
These statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any such statements.
(b) In collaboration with Sanofi (c) The Company is solely responsible for the development and commercialization of Praluent in the United States and Sanofi is responsible for the development and commercialization of Praluent outside the United States.
Product is known as REGEN-COV in the United States and Ronapreve in other countries.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →